From a Company You Know and Trust

**VistaSeq**

- 27 multi-gene panel
- Efficient and cost-effective approach to genetic cancer testing
- Concise report including interpretation and recommendations

**Experienced Partners**

- Integrated Genetics: A leader in genetic testing and counseling services for more than 25 years
- Integrated Oncology: A leader in complex diagnostic, prognostic, and predictive testing services for cancer

Together we offer

- The largest national commercial genetic counseling team with unparalleled services
- Extensive managed care contracts, helping patients maximize their benefits
- Pre-authorization services to support you and your patients
- A network of more than 1,700 patient service centers

Ordering VistaSeq Hereditary Cancer Panel

**Test Code**
- 481220

**Specimen Requirements**
- 7 mL whole blood in a lavender-top (EDTA) tube

To learn more about VistaSeq Hereditary Cancer Panel, BRCAssure® BRCA1/2 Analysis or other Integrated Genetics and Integrated Oncology genetic tests, please visit www.integratedgenetics.com or www.integratedoncology.com.

If you are interested in genetic counseling services, please call 855-GC-CALLS or 855-422-2557.

**REFERENCES**


Because Knowledge is a Powerful Tool.

**VistaSeq** Hereditary Cancer Panel provides an assessment of genetic mutations within a panel of 27 genes known to be associated with hereditary cancer syndromes.
Hereditary Cancer Syndromes

The mapping of the human genome has provided medical professionals with the ability to refine a patient’s cancer risk through an analysis of inherited (germline) mutations. Approximately 5 to 10 percent of cancers are thought to be caused by mutations in genes that are associated with hereditary cancer syndromes.1

- Genetic mutations have been associated with more than 50 hereditary cancer syndromes.1
- Patients with genetic mutations are at a higher risk of developing certain types of cancer than the general population.
- Genetic tests can help confirm whether a patient’s condition is the result of an inherited cancer syndrome.
- Genetic tests can also help identify family members at risk for developing cancers associated with a hereditary cancer syndrome.

VistaSeq Hereditary Cancer Panel

Indications for testing:

- When a patient’s personal or family medical history suggests a hereditary cancer syndrome
- When a patient’s personal or family history includes several cancer types
- When a patient has suspicious medical history that does not meet clinical testing criteria for a specific hereditary cancer syndrome
- When a patient has tested negative or indeterminate for mutations in a single cancer gene but whose personal and/or family history suggests a hereditary predisposition for cancer

To confirm a diagnosis of an inherited cancer syndrome

To identify family members who may have inherited a cancer-associated mutation

To provide clinicians with an assessment of multiple cancer-associated genes in a cost-effective and timely manner

The NCCN Guidelines® specify that multi-gene testing is ideally offered in consultation with a cancer genetics professional.2

Integrated Genetics and Integrated Oncology provide the largest national commercial genetic counseling team to help patients make informed healthcare decisions.

Call us at 855-GC-CALLS or 855-422-2257.

Identifying Your Patients’ Risk

VistaSeq Hereditary Cancer Panel is a multi-gene test that detects inherited mutations in genes which have been associated with an increased risk of developing hereditary cancers.

Mutations in different genes can cause the same type of cancer; conversely, one gene may be associated with multiple hereditary cancers.

NCCN Guidelines® and The Society of Gynecologic Oncology (SGO) note that hereditary multi-gene panels may be an efficient and cost-effective approach to genetic cancer testing when used in appropriate clinical settings.2,3

The VistaSeq Hereditary Cancer Panel is designed to provide information that can be used to determine if there is an increased cancer risk in patients with an associated personal or family history. It is specifically designed to detect inherited mutations and is not appropriate for the detection of other types of mutations in acquired cancers.

Patients with a family history that is specific to one cancer type may receive more benefit from a focused genetic test such as BRCA1/2 analysis or testing for Lynch syndrome.

Broadening Your Patients’ Options

The VistaSeq Hereditary Cancer Panel is designed to provide information that can be used to determine if there is an increased cancer risk in patients with an associated personal or family history. It is specifically designed to detect inherited mutations and is not appropriate for the detection of other types of mutations in acquired cancers.

Patients with a family history that is specific to one cancer type may receive more benefit from a focused genetic test such as BRCA1/2 analysis or testing for Lynch syndrome.

Because Knowledge is a Powerful Tool

VistaSeq Hereditary Cancer Panel provides an assessment of genetic mutations within a panel of 27 genes known to be associated with hereditary cancer syndromes.
Hereditary Cancer Syndromes

The mapping of the human genome has provided medical professionals with the ability to refine a patient’s cancer risk through an analysis of inherited (germline) mutations. Approximately 5 to 10 percent of cancers are thought to be caused by mutations in genes that are associated with hereditary cancer syndromes.¹

- Genetic mutations have been associated with more than 50 hereditary cancer syndromes.¹
- Patients with genetic mutations are at a higher risk of developing certain types of cancer than the general population.
- Genetic tests can help confirm whether a patient’s condition is the result of an inherited cancer syndrome.
- Genetic tests can also help identify family members at risk for developing cancers associated with a hereditary cancer syndrome.

VistaSeq Hereditary Cancer Panel

Indications for testing:

- When a patient’s personal or family medical history suggests a hereditary cancer syndrome
- When a patient’s personal or family history includes several cancer types
- When a patient has suspicious medical history that does not meet clinical testing criteria for a specific hereditary cancer syndrome
- When a patient has tested negative or indeterminate for mutations in a single cancer gene but whose personal and/or family history suggests a hereditary predisposition for cancer
- To confirm a diagnosis of an inherited cancer syndrome
- To identify family members who may have inherited a cancer-associated mutation
- To provide clinicians with an assessment of multiple cancer-associated genes in a cost-effective and timely manner

Identifying Your Patients’ Risk

VistaSeq Hereditary Cancer Panel is a multi-gene test that detects inherited mutations in genes which have been associated with an increased risk of developing hereditary cancers.

Mutations in different genes can cause the same type of cancer; conversely, one gene may be associated with multiple hereditary cancers.

NCCN Guidelines® and The Society of Gynecologic Oncology (SGO) note that hereditary multi-gene panels may be an efficient and cost-effective approach to genetic cancer testing when used in appropriate clinical settings.¹²³

<table>
<thead>
<tr>
<th>Genes</th>
<th>Breast Cancer</th>
<th>Colorectal Cancer</th>
<th>Ovarian Cancer</th>
<th>Endometrial Cancer</th>
<th>Gastric Cancer</th>
<th>Pancreatic Cancer</th>
<th>Skin Cancer</th>
<th>Prostate Cancer</th>
<th>Other Cancers</th>
</tr>
</thead>
<tbody>
<tr>
<td>APC³</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>ATM³³¹</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>BARD1</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>BMPR1A¹⁴</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>BRCA1¹⁴</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>BRCA2</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>CDKN1A</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>CDKN2A</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>CHEK2</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>EPCAM¹⁴</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>FAM175A³</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>MLH1¹¹</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>MSH2¹</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>MSH6¹</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>MUTYH¹</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>NBN¹¹⁴</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>PALB2¹</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>PMS2²</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>PRKAR1B¹</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>PTEN¹</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>RAD50¹⁴</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>RAD51D¹</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>SMAD4¹⁴</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>STK11¹¹</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>TP53¹</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
</tbody>
</table>

Broadening Your Patients’ Options

The VistaSeq Hereditary Cancer Panel is designed to provide information that can be used to determine if there is an increased cancer risk in patients with an associated personal or family history. It is specifically designed to detect inherited mutations and is not appropriate for the detection of other types of mutations in acquired cancers.

Patients with a family history that is specific to one cancer type may receive more benefit from a focused genetic test such as BRCAssure® BRCA1/2 analysis or testing for Lynch syndrome.
From a Company You Know and Trust

VistaSeq™

- 27 multi-gene panel
- Efficient and cost-effective approach to genetic cancer testing
- Concise report including interpretation and recommendations

Experienced Partners

- Integrated Genetics: A leader in genetic testing and counseling services for more than 25 years
- Integrated Oncology: A leader in complex diagnostic, prognostic, and predictive testing services for cancer
- Together we offer
  - The largest national commercial genetic counseling team with unparalleled services
  - Extensive managed care contracts, helping patients maximize their benefits
  - Pre-authorization services to support you and your patients
- A network of more than 1,700 patient service centers

Ordering VistaSeq Hereditary Cancer Panel

Test Code
- 481220

Specimen Requirements
- 7 ml whole blood in a lavender-top (EDTA) tube

To learn more about VistaSeq Hereditary Cancer Panel, BRCAssure® BRCAl/2 Analysis or other Integrated Genetics and Integrated Oncology genetic tests, please visit www.integratedgenetics.com or www.integratedoncology.com.

If you are interested in genetic counseling services, please call 855-GC-CALLS or 855-422-2557.

REFERENCES
11. NNtron, TX et al., 1500 mutations in 420 genes are associated with cancer. Nucleic Acids Res 2013; 41:3086-93.